SpyGlass Pharma reports Q1 loss of $13.8M; Phase 1/2 BIM-IOL data shows 98% drop-free, 34% IOP reduction

SpyGlass Pharma, Inc.

2026-Q1 EPS reported -$0.69

Net loss of $13.8M ($0.69/share) vs $8.8M loss in Q1 2025; R&D expenses $8.5M, G&A $6.9M.
Cash & investments $251M as of Mar 31, 2026, funded through 2028 after $172.5M IPO in Feb 2026.
Phase 1/2 BIM-IOL 12-mo data: 98% drop-free, 34% mean IOP reduction from baseline at 78-mcg dose.
Phase 3 registrational trials SGP-005 and SGP-006 continue; enrollment completion expected in 2027.
Bimatoprost Drug Ring (BIM-DRS) first-in-human trial on track to start H2 2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

SpyGlass Pharma, Inc. reported first quarter ended March 31, 2026 results: net income $13.8 million, EPS ($0.69) per basic and diluted share.

Period: first quarter ended March 31, 2026
Net income: $13.8 million
EPS: ($0.69) per basic and diluted share
Result: reported results

Exact text from the filing

Net Loss was $13.8 million, or ($0.69) per basic and diluted share, for the first quarter of 2026

View on SEC.gov

Browse all earnings releases →

SpyGlass Pharma, Inc. filing history →

Source: SEC EDGAR

accession 0001778922-26-000033

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.